SureTrader SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Vascular Biogenics Ltd. (VBLT)

VBLT RSS Feed
Add VBLT Price Alert      Hide Sticky   Hide Intro
Moderator: gr8db8
Search This Board:
Last Post: 1/15/2017 7:32:40 PM - Followers: 30 - Board type: Free - Posts Today: 0

Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its clinical pipeline is based on two platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. As of June 6, 2014, it has developed two programs based on these platforms an oncology program and an anti-inflammatory program. Its lead product candidate from its oncology program, VB-111, is a gene-based biologic that is initially developing for recurrent glioblastoma (rGBM), an aggressive form of brain cancer. The Company has also received orphan drug designation in both the United States and Europe. The Company’s oncology program is based on its Vascular Targeting System (VTS), platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. http://www.vblrx.com
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VBLT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
VBLT News: Report of Foreign Issuer (6-k) 01/09/2017 09:02:37 AM
VBLT News: VBL Therapeutics Provides Year End 2016 Corporate Update 01/09/2017 07:00:00 AM
VBLT News: Report of Foreign Issuer (6-k) 01/06/2017 07:06:58 AM
VBLT News: VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE Study 01/06/2017 07:00:00 AM
VBLT News: VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM 12/05/2016 07:00:00 AM
PostSubject
#553  Sticky Note Update letter to shareholders this morning from our mjw007 01/09/17 10:11:48 AM
#575   Since u don't need to pass blood brain Oren1976 01/15/17 07:32:40 PM
#574   There is a huge difference between patients with Oren1976 01/15/17 07:29:17 PM
#573   They are able to bring virus to endothelial Oren1976 01/15/17 07:26:19 PM
#572   What other virus(es) do you propose? gr8db8 01/15/17 06:14:49 PM
#571   I thought about an idea - your thoughts. Oren1976 01/14/17 02:21:24 AM
#570   Why is VB-111 better than current treatment options? gr8db8 01/11/17 10:17:45 PM
#569   Yes, I saw this case. However, I clicked davidal66 01/11/17 01:32:44 PM
#568   FWIW ... I think VBLT is more promising gr8db8 01/11/17 12:13:54 PM
#567   Regarding VB-111 and checkpoint inhibitor, any knowledge/guess as gr8db8 01/11/17 11:49:28 AM
#566   Regarding the VB-600 series, I think it would gr8db8 01/11/17 11:43:27 AM
#565   I love seeing news on people experiencing CRs gr8db8 01/11/17 11:39:09 AM
#564   Interesting indeed ! Nice to see a little pick mjw007 01/11/17 11:05:27 AM
#563   If you look at the phase II trial, davidal66 01/11/17 12:51:16 AM
#562   AF is definitely well known in biotech (and gr8db8 01/11/17 12:34:17 AM
#561   Thanks for sharing the good news! I hope gr8db8 01/11/17 12:27:58 AM
#560   Interesting. Af was right on SRPT approval(I was davidal66 01/10/17 06:30:29 PM
#559   One piece of good news. The complete response davidal66 01/10/17 06:01:19 PM
#558   Regarding Adam Feuerstein because his comments about VBLT gr8db8 01/10/17 05:51:15 PM
#557   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732255/ Just a hunch... it invo davidal66 01/10/17 12:50:55 AM
#556   The third bullet point is certainly a teaser: gr8db8 01/09/17 11:27:42 AM
#555   Hear u Also like this language! VBL's pipeline also mjw007 01/09/17 11:18:06 AM
#554   I like the 3 milestones for 2017 and gr8db8 01/09/17 11:15:45 AM
#553   Update letter to shareholders this morning from our mjw007 01/09/17 10:11:48 AM
#552   Having thought about it a bit more, I davidal66 01/08/17 02:05:39 PM
#551   So 2 scenarios would trigger interim: gr8db8 01/07/17 03:13:37 PM
#550   davidal66 ... I think you're reading it right. gr8db8 01/06/17 06:56:54 PM
#549   Thanks for that analysis! Hope you stay and contribute. gr8db8 01/06/17 06:50:41 PM
#548   I'm a new member here. I enjoyed NewMember 01/06/17 02:20:52 PM
#547   GR, I get the 105 deaths, but what davidal66 01/06/17 01:15:24 PM
#546   Not sure how the speed of this enrollment, mjw007 01/06/17 12:18:23 PM
#545   Real news is FDA approval of when interim gr8db8 01/06/17 11:32:21 AM
#544   The advantage over control in vb111 will show Oren1976 01/04/17 12:24:46 AM
#543   That is possible. Whatever they're using the funds gr8db8 01/04/17 12:13:10 AM
#542   What about this scenario... say Dror is getting davidal66 01/03/17 07:13:36 PM
#541   Regarding NASH, the CEO indicated that they want gr8db8 01/03/17 06:23:50 PM
#540   davidal66 ... I would agree that the additional gr8db8 01/03/17 04:58:14 PM
#539   Speculation on the need for money?? davidal66 01/02/17 10:31:09 PM
#538   Thanks for the post. The wild card of davidal66 01/02/17 10:27:59 PM
#537   Thanks for your post I too am somewhat mjw007 01/02/17 05:46:44 PM
#536   2017 - looking ahead gr8db8 01/02/17 05:15:11 PM
#535   I think recruitment is complete. Clinical trials may davidal66 12/27/16 06:33:42 PM
#534   Speaking of filling up fast, Stanford is no gr8db8 12/27/16 05:21:01 PM
#533   True, one more little interesting thing. Dr. Brenner--who davidal66 12/27/16 01:21:05 PM
#532   100% agree with your assessment davidal66. Phase 3 gr8db8 12/27/16 12:17:09 PM
#531   I know the Northwest vaccine is very suspect davidal66 12/26/16 10:48:41 PM
#530   Not quite.... IMHO, I believe the dCVax-L phase davidal66 12/26/16 10:43:24 PM
#529   davidal66 12/26/16 10:43:10 PM
#528   Not a direct answer to your question, but gr8db8 12/26/16 06:20:23 PM
#527   Totally agreed, although adding a few more events davidal66 12/12/16 02:39:34 PM
#526   No, you're right about total recruitment; they're still gr8db8 12/12/16 02:29:16 PM
PostSubject